News
Nevro Receives FDA 510(k) Clearance To Use SI Fixation System Without Need To Include Lateral Screw
28 Feb 24
Biotech, News, FDA, General
Analyst Scoreboard: 4 Ratings For Nevro
22 Feb 24
Analyst Ratings
Nevro Q4 2023 GAAP EPS $(0.25) Beats $(0.49) Estimate, Sales $116.18M Beat $112.48M Estimate
21 Feb 24
Earnings, Earnings Beats, News
Nevro: Q4 Earnings Insights
21 Feb 24
Earnings
Earnings Scheduled For February 21, 2024
21 Feb 24
Earnings
Nevro Announces Coverage Update From Carelon Healthcare For The Treatment Of Painful Diabetic Neuropathy
18 Jan 24
Biotech, News, General
Nevro To Highlight 25 Scientific Abstracts At 2024 North American Neuromodulation Society Annual Meeting
17 Jan 24
Biotech, News, Events, General
What Analysts Are Saying About Nevro Stock
12 Jan 24
Analyst Ratings
RBC Capital Downgrades Nevro to Sector Perform, Lowers Price Target to $20
12 Jan 24
News, Downgrades, Price Target, Analyst Ratings
Nevro Announces Restructuring, Including Laying Off 63 Employees By End Of Q1 2024
9 Jan 24
News
Press releases
Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic Neuropathy
1 Feb 24
Press Releases
Nevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024
29 Jan 24
Press Releases
Top 4 Spinal Injury Stocks for 2024 Watchlist (NRX.V, NVRO, SYK, BSX)
22 Jan 24
News, Press Releases
Top 4 Spinal Injury Stocks for 2024 (NRX.V, NVRO, SYK, BSX)
22 Jan 24
Nevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic Neuropathy
18 Jan 24
Press Releases
Nevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual Meeting
17 Jan 24
Press Releases
Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results
9 Jan 24
Earnings, Press Releases
Nevro to Present at 42nd Annual J.P. Morgan Healthcare Conference
4 Jan 24
Press Releases